Keys to drug sensitivity from updated functional work flows

Same author

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Leukemia·2026

Same author

Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.

Nature cancer·2026

Same author

A multi-center study on the consistency of drug sensitivity testing in patients with acute myeloid leukemia.

NPJ precision oncology·2026

Same author

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Blood neoplasia·2026

Same author

Biomedical Data Manifest: A lightweight data documentation mapping to increase transparency for AI/ML.

Scientific data·2026

Same author

DDX41-Mutated AML: A Case Report and Perspectives.

JCO precision oncology·2026

Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026

Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026

Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026

Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026

Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026

Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026

Related Experiment Videos

Keys to drug sensitivity from updated functional work flows

Related Concept Videos

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.

A multi-center study on the consistency of drug sensitivity testing in patients with acute myeloid leukemia.

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Biomedical Data Manifest: A lightweight data documentation mapping to increase transparency for AI/ML.

DDX41-Mutated AML: A Case Report and Perspectives.

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Related Experiment Videos

Keys to drug sensitivity from updated functional work flows

Related Concept Videos

Related Articles

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.

A multi-center study on the consistency of drug sensitivity testing in patients with acute myeloid leukemia.

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Biomedical Data Manifest: A lightweight data documentation mapping to increase transparency for AI/ML.

DDX41-Mutated AML: A Case Report and Perspectives.

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.